yttrium radioisotopes has been researched along with Adverse Drug Event in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aucejo, FN; Cheah, G; Kim, R; Lance, C; Levitin, A; McLennan, G; Menon, KV; Obuchowski, N; Sands, M; Shrikanthan, S; Spain, J; Srinivas, S | 1 |
| Chung, JS; Kim, JS; Kim, SJ; Kim, WS; Kwak, JY; Lee, JJ; Oh, SY; Suh, C; Yang, DH | 1 |
1 trial(s) available for yttrium radioisotopes and Adverse Drug Event
| Article | Year |
|---|---|
Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Pilot Projects; Prednisolone; Survival Rate; Treatment Outcome; Vincristine; Young Adult; Yttrium Radioisotopes | 2012 |
1 other study(ies) available for yttrium radioisotopes and Adverse Drug Event
| Article | Year |
|---|---|
Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Radiation Injuries; Radiopharmaceuticals; Radiotherapy; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States; Yttrium Radioisotopes | 2011 |